Safety of Simvastatin in LAM and TSC (SOS)

• ClinicalTrials.gov Identifier: NCT02061397
• Recruitment Status: Completed
• First Posted: February 12, 2014
• Results First Posted: August 25, 2020
• Last Update Posted: August 25, 2020
• Sponsor: University of Pennsylvania
• Collaborator: The LAM Foundation
• Information provided by (Responsible Party): University of Pennsylvania

Study Description

Brief Summary:

The purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus. This is the first step in looking at simvastatin as a drug that may help patients, by impacting the growth and survival of cells that make up the lung lesions that cause problems in LAM and TSC patients. The study also seeks to learn more about how simvastatin works, when given to patients being treated with everolimus or sirolimus, and to evaluate the safety and any potential benefit to patients taking this 2-drug combination.

The primary objective of this study is to determine the safety of simvastatin in the treatment of LAM-S or LAM-TS in patients on a stable (for at least 3 months) dose of sirolimus or everolimus.

Secondary objectives include:

• To assess the effect of simvastatin on forced expiratory volume in 1 second (FEV1).
• To assess the effect of simvastatin on forced vital capacity (FVC).
• To assess the effect of simvastatin on diffusing lung capacity (DLCO).
• To assess the effect of simvastatin on vascular endothelial growth factor -D (VEGF-D) serum levels.
• To assess the effect of simvastatin with questionnaire- based assessments of dyspnea, fatigue, and quality of life (QOL).
• Assess signs of clinical benefit.

Condition or disease	Intervention/treatment	Phase
Lymphangioleiomyomatosis; Tuberous Sclerosis Complex	Drug: Simvastatin; Drug: Sirolimus Oral Product; Drug: Everolimus Oral Product	Phase 1; Phase 2

Detailed Description:

After providing written informed consent, study related tests/procedures will be done to ensure eligibility for the study. If found to be eligible, the participant will be given simvastatin at a starting dose of 20 mg, to be taken each evening by mouth. If after 2 months the simvastatin 20 mg dose is tolerated, the dose of simvastatin will be increased to 40 mg each evening by mouth. Doses may be adjusted as needed, should the participant experience side effects from simvastatin. The participant's dose of everolimus or sirolimus is not expected to change, as this is a dose that has been previously tolerated. If side effects occur as a result of the combination of drugs, the dosages may be adjusted by the study physician (investigator).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)
• Study Start Date: March 2014
• Actual Primary Completion Date: December 13, 2019
• Actual Study Completion Date: December 13, 2019

Arms and Interventions

Arm

Intervention/treatment

Experimental: simvastatin treatment arm; Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.

Drug: Simvastatin; Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.; Other Name: trade name Zocor; Drug: Sirolimus Oral Product; Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.; Other Name: Rapamune; Drug: Everolimus Oral Product; Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.; Other Name: Afinitor

Outcome Measures

Primary Outcome Measures :

1. Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients [ Time Frame: 5 months ]
   Safety is a primary outcome measure which will be assessed by any major changes or deterioration in patient health.

Secondary Outcome Measures :

1. Percent Predicted FEV1 [ Time Frame: 5 months ]
   Lung function will be measured by FEV1: forced expiratory volume in 1s mean and calculated as % predicted +_ SD (standard deviation).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Female, age 18 and older with clinically definitive diagnosis (biopsy proven or compatible chest CT/MRI scan) of sporadic LAM (LAM-S) or LAM associated with TS (LAM-TS).
• Treated with a stable (at least 3 months) dose of sirolimus or everolimus
• Negative pregnancy test (women of child bearing potential) at screening.
• Women of childbearing potential must be using barrier, medically acceptable contraceptive precautions.
• Signed and dated informed consent.

Exclusion Criteria:

• Age < 18 years
• Known allergy to simvastatin or currently taking simvastatin, or therapy with a medication in the same class as simvastatin within the past 30 days.
• Allergy to sirolimus or everolimus.
• Current use of other than sirolimus or everolimus investigational drug for TSC or LAM within the past 30 days.
• Use of estrogen containing medications, including birth control pills, within the 30 days prior to enrollment.
• Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, warfarin, sildenafil or use of strong CYP3A4 inhibitors including gemfibrozil, cyclosporine, danazol, verapamil, diltiazem, and dronedarone. amiodarone, amlodipine, and ranolazine.
• Participation in another clinical study(ies) of an investigational treatment or drug within 30 days prior to the screening visit.
• Amiodarone; within the past 30 days.
• Significant dysfunction of liver (ALT > 2 times upper limit of normal-ULN), kidney (serum creatinine > 1.5 times ULN), or blood (leucopenia (ANC<2000), anemia, Hgb < 11 gm/dl).
• History of inflammatory muscle disease or myopathy.
• Bleeding diathesis or anticoagulant therapy.
• Uncontrolled hyperlipidemia or diabetes.
• Pregnant, breast feeding, or plan to become pregnant within the next 6 months
• Inadequate contraception (must agree to barrier method)
• History of organ transplant.
• Active on transplant list.
• Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol.
• Unstable seizures (recent changes in pattern or anti-epileptics).
• Mental illness or cognitive deficit precluding informed consent..
• Inability to attend scheduled clinic visits or comply with study procedures.

Contacts and Locations

Locations

United States, Pennsylvania

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

University of Pennsylvania

The LAM Foundation

Investigators

• Principal Investigator: Vera P Krymskaya, PhD, MBA; University of Pennsylvania
• Study Director: Maryl Kreider, MD, MSCE; University of Pennsylvania
• Study Chair: Frank McCormack, MD; University of Cincinnati

  Study Documents (Full-Text)

Documents provided by University of Pennsylvania:

Study Protocol and Statistical Analysis Plan  [PDF] October 4, 2016

Informed Consent Form  [PDF] October 4, 2016

More Information

Publications of Results:

Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol. 2011 Jun;31(12):2484-98. doi: 10.1128/MCB.01061-10. Epub 2011 Apr 11.

Other Publications:

Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol. 2012 May;46(5):563-5. doi: 10.1165/rcmb.2011-0381ED. No abstract available.

Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.

Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.

• Responsible Party: University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT02061397
• Other Study ID Numbers: The SOS Trial
• First Posted: February 12, 2014
• Results First Posted: August 25, 2020
• Last Update Posted: August 25, 2020
• Last Verified: August 2020

Keywords provided by University of Pennsylvania:

lymphangioleiomyomatosis (LAM); tuberous sclerosis complex (TSC); simvastatin; sirolimus; everolimus

Additional relevant MeSH terms:

Simvastatin; Tuberous Sclerosis; Lymphangioleiomyomatosis; Sclerosis; Pathologic Processes; Hamartoma; Neoplasms; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Malformations of Cortical Development, Group I; Malformations of Cortical Development; Nervous System Malformations; Nervous System Diseases; Neurocutaneous Syndromes; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Congenital Abnormalities; Genetic Diseases, Inborn; Lymphangiomyoma; Lymphatic Vessel Tumors; Neoplasms by Histologic Type; Perivascular Epithelioid Cell Neoplasms; Neoplasms, Connective and Soft Tissue; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Sirolimus; Everolimus; MTOR Inhibitors